Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lifemd, Inc. (LFMD)
:LFMD
Holding LFMD?
Track your performance easily
LFMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.99 - $12.88
Previous CloseN/A
Volume302.38K
Average Volume (3M)644.50K
Market Cap
$204.87M
Enterprise Value$209.51M
Total Cash (Recent Filing)$182.56K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Apr 08, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding43,312,120
10 Day Avg. Volume619,661
30 Day Avg. Volume644,495
Standard Deviation0.49
R-Squared0.03
Alpha0.09
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.10
Price to Cash Flow (P/CF)8.60
P/FCF Ratio15.90
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue1.09
Enterprise Value/Gross Profit1.57
Enterprise Value/Ebitda-21.07
Forecast
1Y Price Target
$10.75Price Target Upside123.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
LifeMD News
PremiumCompany Announcements
LifeMD Sets New CEO Compensation Strategy
Bulls Say, Bears Say
Bulls Say
Competitive AdvantageManagement reinforced its 'Weight Management' program is differentiated from competitors due to much greater focus on clinical services, which management believes will shield LFMD more versus peers.
Financial PerformanceManagement reiterated 2024 revenue guidance of at least $205M, with adjusted EBITDA now in the range of $13-14M.
Market GrowthLifeMD has accelerated growth due to the successful uptake of its virtual 'GLP-1 Weight Management' program within its core Telehealth segment.
Bears Say
Insurance And Affordability IssuesManagement believes another major challenge for LFMD is patient affordability for the high price of branded GLP-1 drugs when insurance does not cover it.
Regulatory ChallengesThe FDA ruling is seen as modestly negative for LFMD, as the company has 90 days to convert its patients on compounded tirzepatide to branded tirzepatide or alternative compounded GLP-1s.
Revenue Sustainability ConcernsInvestors are questioning the sustainability of revenue streams for LifeMD and other companies selling compounded forms of tirzepatide.
---
Ownership Overview
13.55% Insiders
8.74% Mutual Funds
0.53% Other Institutional Investors
69.62% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Ability to SellRisks related to the company’s ability to sell goods and services
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LFMD FAQ
What was Lifemd, Inc.’s price range in the past 12 months?
Lifemd, Inc. lowest stock price was $3.99 and its highest was $12.88 in the past 12 months.
What is Lifemd, Inc.’s market cap?
Lifemd, Inc.’s market cap is $204.87M.
When is Lifemd, Inc.’s upcoming earnings report date?
Lifemd, Inc.’s upcoming earnings report date is Apr 08, 2025 which is in 80 days.
How were Lifemd, Inc.’s earnings last quarter?
Lifemd, Inc. released its earnings results on Nov 07, 2024. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.118 by -$0.022.
Is Lifemd, Inc. overvalued?
According to Wall Street analysts Lifemd, Inc.’s price is currently Undervalued.
Does Lifemd, Inc. pay dividends?
Lifemd, Inc. does not currently pay dividends.
What is Lifemd, Inc.’s EPS estimate?
Lifemd, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Lifemd, Inc. have?
Lifemd, Inc. has 43,312,120 shares outstanding.
What happened to Lifemd, Inc.’s price movement after its last earnings report?
Lifemd, Inc. reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.118. Following the earnings report the stock price went up 14.035%.
Which hedge fund is a major shareholder of Lifemd, Inc.?
Among the largest hedge funds holding Lifemd, Inc.’s share is Royce & Associates LLC. It holds Lifemd, Inc.’s shares valued at 5M.
---
LifeMD Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.75 (123.03% Upside)
$10.75 (123.03% Upside)
Blogger Sentiment
Bullish
LFMD Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 352.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $292.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.30%
12-Months-Change
Fundamentals
Return on Equity
301.60%
Trailing 12-Months
Asset Growth
78.32%
Trailing 12-Months
Company Description
Lifemd, Inc.
Conversion Labs, Inc. engages in the manufacturing, distribution, and sale of natural immune support products containing proprietary yeast beta glucans. Its products are oral intake tablets and topical creams, and gels for skin application. It operates through the Finished Cosmetic Products and Nutraceutical and Cosmetic Additives segments. The company was founded in 1987 and is headquartered in New York, NY.
---
LFMD Company Deck
---
LFMD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in LifeMD's telehealth business, with significant revenue growth, improved profitability, and strategic expansions in pharmacy operations. However, challenges remain with GLP-1 therapy coverage and maintaining growth in WorkSimpli's subscriber base. Despite these issues, the overall sentiment leans positive due to robust growth and financial results.Read More>---
LFMD Stock 12 Month Forecast
Average Price Target
$10.75
▲(123.03% Upside)
Technical Analysis
Hims & Hers Health
―
Teladoc
―
Doximity
―
American Well
―
DENTSPLY SIRONA
―
Pediatrix Medical Group
―
Best Analysts Covering LFMD
1 Year
1 Year Success Rate
8/30 ratings generated profit
1 Year Average Return
+17.34%
reiterated a buy rating 3 months ago
Copying David Larsen's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of +17.34% per trade.
---